Polycystic ovary syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Polycystic ovary syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polycystic ovary syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polycystic ovary syndrome: Overview
Polycystic ovary syndrome (PCOS) is a condition that affects a woman’s hormone levels. Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility. Some of the symptoms of PCOS include: Irregular menstrual cycle, too much hair on the face, chin, or parts of the body where men usually have hair, Acne on the face, chest, and upper back, Weight gain or difficulty losing weight, Darkening of skin, particularly along neck creases, in the groin, and underneath breasts. There is no single test to diagnose PCOS. To help diagnose PCOS and rule out other causes of symptoms, medical history and physical exam is evaluated and different tests are performed. There is no cure for PCOS, but the symptoms of PCOS can be managed.
'Polycystic ovary syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovary syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovary syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovary syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovary syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Polycystic ovary syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycystic ovary syndrome Emerging Drugs
Further product details are provided in the report
Polycystic ovary syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Polycystic ovary syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Polycystic ovary syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovary syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovary syndrome drugs.
Polycystic ovary syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Polycystic ovary syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polycystic ovary syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Polycystic ovary syndrome: Overview
Polycystic ovary syndrome (PCOS) is a condition that affects a woman’s hormone levels. Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility. Some of the symptoms of PCOS include: Irregular menstrual cycle, too much hair on the face, chin, or parts of the body where men usually have hair, Acne on the face, chest, and upper back, Weight gain or difficulty losing weight, Darkening of skin, particularly along neck creases, in the groin, and underneath breasts. There is no single test to diagnose PCOS. To help diagnose PCOS and rule out other causes of symptoms, medical history and physical exam is evaluated and different tests are performed. There is no cure for PCOS, but the symptoms of PCOS can be managed.
'Polycystic ovary syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovary syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovary syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovary syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovary syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic ovary syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic ovary syndrome.
This segment of the Polycystic ovary syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycystic ovary syndrome Emerging Drugs
- DLBS3233: Dexa Medica
- Elagolix: Abbvie/ Neurocrine Biosciences
Further product details are provided in the report
Polycystic ovary syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Polycystic ovary syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Polycystic ovary syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Polycystic ovary syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovary syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovary syndrome drugs.
Polycystic ovary syndrome Report Insights
- Polycystic ovary syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Polycystic ovary syndrome drugs?
- How many Polycystic ovary syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovary syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovary syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polycystic ovary syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Polycystic ovary syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polycystic ovary syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polycystic ovary syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polycystic ovary syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DLBS3233: Dexa Medica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Elagolix: Abbvie/ Neurocrine Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Polycystic ovary syndrome Key Companies
Polycystic ovary syndrome Key Products
Polycystic ovary syndrome- Unmet Needs
Polycystic ovary syndrome- Market Drivers and Barriers
Polycystic ovary syndrome- Future Perspectives and Conclusion
Polycystic ovary syndrome Analyst Views
Polycystic ovary syndrome Key Companies
Appendix
Executive Summary
Polycystic ovary syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polycystic ovary syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polycystic ovary syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polycystic ovary syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DLBS3233: Dexa Medica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Elagolix: Abbvie/ Neurocrine Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Polycystic ovary syndrome Key Companies
Polycystic ovary syndrome Key Products
Polycystic ovary syndrome- Unmet Needs
Polycystic ovary syndrome- Market Drivers and Barriers
Polycystic ovary syndrome- Future Perspectives and Conclusion
Polycystic ovary syndrome Analyst Views
Polycystic ovary syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Polycystic ovary syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Polycystic ovary syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Polycystic ovary syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Polycystic ovary syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
